Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLAUDICATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,531 records · Page 85Linked to original sources
PubMed2003

[Antiischemic efficacy of trimetazidine in patients with intermittent claudication and effort angina].

Male patients (n=42) with atherosclerosis obliterans and stage IIA-III ischemia of lower extremities combined with class II-III angina pectoris were divided into 2 groups. Patients of group 1 (n=21) were given simvastatin (10-20 mg/day), clopidogrel (75 mg/day) and trimetazidine (60 mg/day) for 6 months, those of group 2 - simvastatin and clopidogrel also for 6 months. Statistically significant decreases of frequency of attacks of angina, nitroglycerine consumption and increases of walking distance occurred only in group 1.

Aged↗
PubMedDate not supplied

Pharmacological treatment of intermittent claudication: double blind controlled study of Sulodexide vs placebo.

A double blind placebo controlled randomized study was used to assess the clinical variations caused by Sulodexide treatment (100 mg/die) vs placebo in 30 patients with a mean age of 50.3 years suffering from peripheral arterial obstructive disease of the lower limbs (II stage). The general tolerance of the therapy was monitored over the medium-term. There were marked changes in the clinical signs and symptoms in the Sulodexide group, which showed a gradual constant improvement, while they were stationary in the placebo group. Confirmation of the marked improvement in the Sulodexide group was provided by the Winsor index which showed a significant increase in these patients while only a minimum variation was observed in the placebo group. The positive antithrombotic action of the active treatment led to an increase in the blood supply in previously ischemic regions, without creating haemorrhagic risks or disturbing the haemostatic balance. The absence of adverse reactions and good systemic tolerance is also noteworthy.

Adult↗